<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02576327</url>
  </required_header>
  <id_info>
    <org_study_id>PKU-2015YJZ25</org_study_id>
    <nct_id>NCT02576327</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation</brief_title>
  <official_title>A Multi-central Perspective Randomized Controlled Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jun Zhu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of additional aprepitant to
      standard antiemetic regimen in Autologous Hematopoietic Stem Cell Transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chemotherapy-induced nausea and vomiting (CINV) is a serious complication of treatments of
      hematological malignancies. Although aprepitant has been shown to control CINV in highly
      emetogenic therapies for solid tumors, the antiemetic effect of aprepitant in hematological
      chemotherapies is still not clear. In this multi-central perspective randomized controlled
      study, the investigators are trying to evaluate the efficacy and safety of additional
      aprepitant to standard antiemetic regimen in Autologous Hematopoietic Stem Cell
      Transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall complete response (no emesis and no rescue therapy)</measure>
    <time_frame>During and post chemotherapy (0-120 h)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to initial neutrophil engraftment</measure>
    <time_frame>30 days post-transplantation</time_frame>
    <description>Time to initial neutrophil engraftment is defined as 1st of 3 consecutive days of an ANC ≥0.5 × 10^9/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to initial platelet recovery</measure>
    <time_frame>30 days post-transplantation</time_frame>
    <description>Time to initial platelet recovery is defined as 1st of 3 consecutive platelet count measurements tested on different days with a count ≥20 × 10^9/L with no platelet transfusion in the prior 7 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>During and post chemotherapy (0-120 h)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability assessed by possible side effects, and all AE will be reported during 30 days after the chemotherapy.</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Vomiting</condition>
  <arm_group>
    <arm_group_label>Aprepitant Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tropisetron 5mg（Day1-6）+ Dexamethasone 10mg（Day1-6）+ Aprepitant125mg（Day1-2）、80mg（Day3-6）</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tropisetron 5mg（Day1-6）+ Dexamethasone 10mg（Day1-6）</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tropisetron</intervention_name>
    <description>Tropisetron Hydrochloride Injection 5mg (Day 1-6)</description>
    <arm_group_label>Aprepitant Arm</arm_group_label>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>Tropisetron Hydrochloride Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone Sodium Phosphate Injection 10mg (Day 1-6)</description>
    <arm_group_label>Aprepitant Arm</arm_group_label>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>Dexamethasone Sodium Phosphate Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant</intervention_name>
    <description>Aprepitant 125mg （Day1-2）, 80mg (Day 3-6)</description>
    <arm_group_label>Aprepitant Arm</arm_group_label>
    <other_name>Emend</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women &gt;/= 18 years, &lt;65 years

          -  Patients with lymphoma receiving autologous hematopoietic stem cell transplantation
             for the first time

          -  ECOG 0-2

          -  TBIL,AST and ALT &lt; 2.5-fold upper normal range

          -  Female and male subjects of childbearing potential must agree to use a medically
             accepted method of adequate contraception.

          -  Signed informed consent

        Exclusion Criteria:

          -  Prior autologous/ allogeneic hematopoietic stem cell transplantation for lymphoma

          -  Women who are pregnant or breast feeding.

          -  Serious or uncontroled infection

          -  Serious complications

          -  Severe renal or hepatic disease

          -  Severe mental or nervous system diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Zhu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2015</study_first_submitted>
  <study_first_submitted_qc>October 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2015</study_first_posted>
  <last_update_submitted>December 28, 2016</last_update_submitted>
  <last_update_submitted_qc>December 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Jun Zhu</investigator_full_name>
    <investigator_title>Department of Hematology Oncology, clinical oncology college, Director of department, Party Secretary</investigator_title>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>Aprepitant</keyword>
  <keyword>Chemotherapy-induced nausea and vomiting (CINV)</keyword>
  <keyword>Autologous Hematopoietic Stem Cell Transplantation</keyword>
  <keyword>Hematological Malignancies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Tropisetron</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

